FDA, Genentech warn on Raptiva

The FDA announced new warnings on the Genentech psoriasis drug Raptiva following reports of four cases of hemolytic anemia diagnosed four to six months after patients started on the monoclonal antibody. Two of the cases occurred in clinical trials of Raptiva, and two were reported as post-marketing events, the FDA said.